Julia Stephanus
Partner
Borealis Ventures
Julia has been a visionary entrepreneur and strategic brand builder in the veterinary industry for 30+ years. Her achievements include building and scaling two successful start-up veterinary pharmaceutical businesses and launching 28 veterinary products. She was Founder and CEO of Summit VetPharm, which exited to Ceva Animal Health in 2010. As Chief Commercial Officer of Aratana Therapeutics (PETX), she was instrumental in the IPO and the buildout of a fully integrated commercial organization. Julia led the co-promotion and the licensing of Aratana’s lead osteoarthritis product, Galliprant®, to Elanco. Aratana exited to Elanco in 2019.
Julia is Founder and President of Avviare, LLC, providing consulting services to start-ups and established players in veterinary biopharmaceuticals. In addition to the start-up experience, Julia’s career includes senior-level positions at Ceva, Forest Laboratories (Allergan) and Pfizer Animal Health (Zoetis) and their legacy companies.
Julia presently serves on the Boards of PBI Gordon, ReduxBio, and Jenga Biosciences. Julia is a Founding Director and Board Member of Feather in Her Cap, recognizing outstanding women in Animal Health.
Julia received her Bachelor of Arts from Indiana University in Bloomington, Indiana, with additional education at the Wharton School of Business, Columbia University, the University of Chicago, and Harvard University.
Natacha Gaillard
Co-Founder and Co-CEO
ASTRA Therapeutics
Transboundary animal diseases (TADs) such as avian influenza, bluetongue virus, and foot-and-mouth disease pose serious risks to animal health, livestock production, and public health. Past outbreaks have exposed gaps in disease awareness and preparedness, with farmers often bearing the greatest impact. Effective prevention, through international collaboration, biosecurity, vaccination, and surveillance, requires coordinated action to stop the spread and support eradication efforts.
Moderator
Albert Picado
Principal Scientist Viral Diseases Research
Boehringer Ingelheim
Albert Picado is a Veterinary Epidemiologist with over 20 years of experience in designing and conducting epidemiological studies, as well as in the development, evaluation, and implementation of control tools for infectious diseases affecting both animals and humans. Currently serving as Principal Scientist within the Viral Diseases Research (VDR) team at Boehringer Ingelheim in Lyon (France), Albert provides strategic epidemiological support for the development of vaccines targeting priority infectious diseases. His work includes a strong focus on Transboundary Animal Diseases (TADs), contributing to global efforts to improve disease prevention and control through innovative vaccine solutions.
Panellists
Damian Tago
Biosecurity and Animal Health Economics Coordinator
FAO
Paul Horwood
UK Head of Farm
IVC Evidensia
Our panellists will discuss where data and AI are going to have the greatest impact across the value chain, from Discovery to Delivery.
- AI’s impact on reducing the timeline between adoption of innovation in Human Health and Animal Health
- Improving capital efficiency - rethinking the R&D process with AI
- How common data structure and architecture design will facilitate industry collaboration and unleash the power of existing data
- Improving differential diagnosis at point of care – augmenting, not replacing, practitioner decision making
- Teaching future generations how to deliver care based on new and growing sources of data
Moderator
Etienne Legangneux
CEO
Vet-AI
Panellists
Paul Higgs
Chief Veterinary Officer
CVS Group Plc
Jackie Hunter
CEO
OI Pharma Partners Ltd
Daniel Jamieson
CEO and Founder
Biorelate
Cal Lai
CEO
Ask.vet